Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2016
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 14 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 01 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.